ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 496

Heart Failure Risk Among Patients with Rheumatoid Arthritis: Association with Anti-Rheumatic Drugs

Michael Ahlers1, C. Michael Stein2, Cecilia P. Chung2, Michelle J. Ormseth3, Eric Farber-Eger3 and Deepak Gupta4, 14906 illinois avenue, Vanderbilt University School of Medicine, Nashville, TN, 2Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 3Vanderbilt University Medical Center, Nashville, TN, 4Internal Medicine - Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Antimalarial drugs, DMARDs, Heart disease, rheumatoid arthritis (RA) and steroids

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of coronary artery disease (CAD), but the association with heart failure (HF) is less characterized.  We aimed to identify factors associated with HF risk among patients with RA. 

Methods: Using the Vanderbilt University Medical Center electronic health record, we retrospectively identified 9,492 adult RA patients (median age 56 years, 76% female, 89% white) without prevalent HF at RA diagnosis.  RA diagnosis was defined as ≥2 RA specific ICD-9 codes (714.0-714.2) that were ≥ 14 days apart and an anti-rheumatic medication prescription.  Medication categories were: non-biologic disease modifying anti-rheumatic drug (DMARD) [azathioprine, cyclophosphamide, leflunomide, methotrexate, sulfasalazine]; anti-tumor necrosis factor (TNF) [adalimumab, certolizumab, etanercept, golimumab, infliximab]; antimalarial [chloroquine, hydroxychloroquine, quinacrine]; other biologic/small molecule DMARD [abatacept, anakinra, rituximab, tocilizumab, tofacitinib]; and systemic corticosteroid.  Incident HF was defined as ≥1 ICD-9 code (428.x or 425.x) with diuretic use within 90 days.  The associations between demographic, clinical factors, and medications with the risk of incident HF were quantified with multivariable-adjusted logistic regression. 

Results: Over a median 5.0 (range: 0.1 to 27) years of follow-up, a total of 522 RA patients (5.5%) developed incident HF (Table).  Increasing age, CAD, atrial fibrillation, as well as higher body mass index, heart rate, pulse pressure, and creatinine at baseline (first RA ICD-9 code) were each associated with greater HF risk (Figure).  The risk of HF varied by use of anti-rheumatic medication class before HF.  Non-biologic DMARDs, other biologic/small molecule DMARDs, and systemic corticosteroids were associated with lower HF risk, p ≤ 0.001 for all.  Anti-TNF agents and antimalarials were not associated with the risk of HF, p ≥ 0.10 for both.

Conclusion: RA patients are at risk for HF.  Established cardiovascular disease or traditional risk markers are associated with increased risk.  Anti-rheumatic medications variably associate with HF risk, with lower risk observed among patients taking non-biologic or other biologic/small molecule DMARDs or systemic corticosteroids.

 

 

 

 

 


Disclosure: M. Ahlers, None; C. M. Stein, None; C. P. Chung, None; M. J. Ormseth, None; E. Farber-Eger, None; D. Gupta, None.

To cite this abstract in AMA style:

Ahlers M, Stein CM, Chung CP, Ormseth MJ, Farber-Eger E, Gupta D. Heart Failure Risk Among Patients with Rheumatoid Arthritis: Association with Anti-Rheumatic Drugs [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/heart-failure-risk-among-patients-with-rheumatoid-arthritis-association-with-anti-rheumatic-drugs/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/heart-failure-risk-among-patients-with-rheumatoid-arthritis-association-with-anti-rheumatic-drugs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences